You are here
August 5, 2020
CBS highlights NIH’s launch of ACTIV-2 and ACTIV-3 to develop monoclonal antibody treatment for COVID-19
Dr. Collins talks to CBS’ Jonathan LaPook about the launch of ACTIV-2 and ACTIV-3 inpatient and outpatient clinical trials to test effectiveness of monoclonal antibody treatment for COVID-19.
This page last reviewed on August 6, 2020